All News

As rising drug costs continue to take up a larger portion of the total cost of care, practices in the Oncology Care Model find themselves in control of a shrinking portion of total costs, according to anecdotes from an academic medical center and a community-based practice during the National Comprehensive Cancer Network’s Policy Summit held September 12 in Washington, DC.

Amgen recently announced early phase 3 CANDOR study data, showing the triple-drug combination of carfilzomib (Kyprolis), along with dexamethasone and daratumumab (Darzalex, sold by Janssen), met its primary end point of progression-free survival in patients with relapsed or refractory multiple myeloma, with a 37% reduction in the risk of progression or death.

Using national electronic health record information on more than 40 million patients over a 20-year period, researchers have found that the proportion of Americans older than 18 years who have had a prior HIV test could be as low as 6.4%. However, they noted several limitations of their analysis.

A study investigating the functional connectivity of the praxis network in patients in the early stages of Parkinson’s disease (PD) found that dopaminergic therapy may normalize praxis abilities and related praxis networks during the early stages of the disease by facilitating the propagation of long-term representations of object-related actions to motor execution areas.

The clinical significance of minimal residual disease (MRD) status was recently highlighted in The American Journal of Managed Care®’s Peer Exchange series “A Review of the Treatment for Multiple Myeloma.” During the series, key opinion leaders discussed the clinical implications and significance of MRD testing in patients with multiple myeloma.

The September issue of The American Journal of Managed Care® (AJMC®) featured research on federal healthcare reform that detailed innovative ideas in Medicare, Medicaid, and the Veterans Affairs health system. Here are 5 findings from research published in the issue.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo